2014
Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2011
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH. Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New England Journal Of Medicine 2011, 364: 842-851. PMID: 21366475, DOI: 10.1056/nejmoa1005987.Peer-Reviewed Original ResearchConceptsInjectable risperidoneOral antipsychoticsQuality of lifeSchizoaffective disorderPsychiatrist's choiceSecond-generation antipsychotic agentsMore adverse eventsMore extrapyramidal symptomsPrimary end pointNeurologic side effectsExtrapyramidal adverse effectsRate of hospitalizationVeterans Affairs systemSocial Performance ScaleAdverse eventsExtrapyramidal symptomsOral treatmentAntipsychotic agentsUnstable diseasePsychiatric symptomsHigh riskHospitalizationSide effectsPatientsPsychiatric hospitalChallenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clinical Trials 2011, 8: 196-204. PMID: 21270143, DOI: 10.1177/1740774510392931.Peer-Reviewed Original ResearchConceptsSchizo-affective disorderAntipsychotic medicationUsual careMedication adherenceEffectiveness trialCommon co-morbid illnessesCo-morbid illnessHigh-risk patientsComparative effectiveness trialClinical effectiveness trialVeterans Health AdministrationNew antipsychotic medicationsTreatment of schizophreniaPsychiatric inpatient hospitalizationQuality of lifeHealth care costsElectronic medical recordsLong-term trialsPatient's psychiatristPrimary endpointSecondary endpointsFirst hospitalizationRecent hospitalizationInjectable risperidoneUnstable patients